South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

GSK’s share price is still significantly down on the year, despite very robust H1 results, leaving it looking extremely ...

It will also push ahead with plans to make innovative and modern healthcare within Asia’s reach, says its chief executive ...

GSK plc announced the acquisition of ordinary shares by several key executives under the Company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involved the purchase of ...

The FDA has agreed to fast-track its review of gepotidacin, an oral antibiotic already approved for urinary tract infections, ...

London: GSK plc has announced that a supplemental New Drug Application for gepotidacin has been accepted by the US Food and ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Assembly Biosciences is advancing its herpes drug to Phase II trials after it showed 94% antiviral efficacy in a Phase Ib ...

The 40 Under 40, Rami Fakhouri of Goldman Ismail is honored for his work in products liability.

South Korea is fast becoming a focal point for global biopharmaceutical licensing, with deal values reaching $7.86 billion ...